Ofev Helps to Preserve Lung Function in Progressive ILD Patients, Trial Data Show
Ofev (nintedanib) helped more patients with progressive fibrosing interstitial lung diseases (ILDs) avoid a decline in lung function greater than 10% over the course of a year compared with those given a placebo, according to a new analysis of the Phase 3 INBUILD trial. A separate analysis…